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Highlights 
• Men with diabetes had significantly higher bone marrow fat than non-diabetics. 
• There was no association between bone marrow fat and bone mineral density (BMD) in non-
diabetic men. 
• Bone marrow fat was negatively correlated with BMD in diabetic men. 
• Further understanding of bone marrow fat, BMD and diabetes may improve our understanding of 
the etiology of fractures in diabetics. 
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Abstract 
Elevated vertebral bone marrow fat (BMF) among individuals with osteoporosis has been 
established in histomorphometric studies. Several studies have found a negative correlation 
between BMF and bone mineral density (BMD) at the spine in men and women across different 
age groups.  Animal studies have also observed bone loss with increased BMF in mice with 
induced diabetes. Our study objective was to test the hypothesis that the association between 
BMF and BMD varies by diabetic status. We performed a cross-sectional study of 156 men aged 
74-96 years from the Osteoporotic Fractures in Men study (MrOS) at the Pittsburgh clinical site. 
All men had spine BMF scans using proton magnetic resonance spectroscopy and spine and hip 
BMD scans by dual-energy x-ray absorptiometry. BMF was expressed as lipid to “lipid + water” 
ratio (%). Men were considered diabetic if they self-reported a physician diagnosis of diabetes, 
diabetes medication or had a fasting glucose > 126mg/dl.  Men with diabetes (n=38) had a 
significantly higher spine BMF (58.9 vs. 54.6 %, p=0.0035), spine BMD (1.20 vs. 1.10 g/cm2, 
P=0.007)) and total hip BMD (0.99 vs. 0.94 g/cm2, p=0.04) than those without, while no 
differences were observed for body weight, body mass index or waist circumference. Pearson 
correlation tests showed no significant correlation of spine BMF with age or BMD in non-
diabetics.  Significant inverse correlations were observed between BMF and BMD (-0.30 for 
femoral neck and  -0.39 for total hip) among diabetic men. In conclusion, men with diabetes had 
a higher BMF   compared to non-diabetic men.  The correlation between BMF and BMD 
differed by diabetes status. Further investigation of the association of diabetes with BMF and 
BMD may provide a better understanding of the high fracture rates among individuals with 
diabetes despite their higher BMD. 
 
Keywords:  bone-fat interactions, general population studies, DXA.  
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Introduction 
Osteoblasts and adipocytes share common precursors, mesenchymal stem cells (MSC), 
and the differentiation of MSC occurs in the bone marrow. With advancing age, hematopoietic 
marrow is progressively replaced by fatty marrow with a higher conversion rate into fatty 
marrow in the bone cavity of the appendicular skeleton [1]. In the past decade, studies have 
begun to evaluate the bone-fat association targeting bone marrow fat (BMF) of the lumbar spine 
and femur. Histomorphometric studies performed on iliac crest biopsies demonstrated not only a 
positive correlation between BMF and age, but also an elevated BMF level in persons with 
osteoporosis or low trabecular bone volume [2, 3].  Advancements in imaging technology have 
enabled researchers to non-invasively quantify BMF using proton magnetic resonance 
spectroscopy (1H-MRS) [4-10]. Results from 1H-MRS studies have shown a positive association 
between BMF and age in both sexes [6, 7, 9] as well as higher BMF content among individuals 
with osteoporosis than those without [4-6, 10].  However, the linear association between BMF 
with bone mineral density (BMD) is not well understood. Several studies have reported a 
significant and negative correlation of BMF with areal BMD [4-6, 10, 11], while another study 
showed no correlation once age was accounted for [7].  
Bone marrow fat has also been linked to higher prevalence of vertebral fractures [3, 9, 12, 
13].  Bone loss and increased BMF have been observed in mice with induced diabetes [14-16], 
but much less is known about this association in humans. In a small study of sixteen adults with 
type 1 diabetes and 12 controls, there was no differences in BMF by diabetes status [17].  
However,  there was a negative correlation between femur BMF and both femoral neck and total 
hip BMD in all subjects [17].  Patsch et al showed that diabetics with a prevalent fracture had 
lower unsaturated fat and higher saturated fat than both non-diabetic controls and diabetics 
without a fracture [18].  Subjects with type 2 diabetes are at increased risk of fracture despite 
their high BMD[19, 20] . Many mechanisms have been proposed, but they explain only a 
fraction of this paradoxical relationship [19, 20].  Further research on the interrelationships 
between fat, diabetes and skeletal health may improve our understanding of the underlying 
mechanisms whereby diabetics are at an increased risk of fracture.   Our current cross-sectional 
study aimed to examine the relationship of BMF with hip and spine BMD and to determine 
whether diabetic status influences this association among   men enrolled in the Osteoporotic 
Fractures in Men study (MrOS). 
 
Materials and Methods 
Study population 
Participants in this study were recruited from the Pittsburgh site of the Osteoporotic 
Fractures in Men (MrOS) study. The MrOS study is a prospective cohort study designed to 
identify risk factors associated with osteoporosis and osteoporotic fractures in older men. From 
March 2000 to April 2002, 5,994 older men were recruited from 6 sites across the US 
(Birmingham, AL, Minneapolis, MN, Palo Alto, CA, Pittsburgh, PA, Portland, OR, and San 
Diego, CA). Recruitment was accomplished primarily through targeted mailings based on motor 
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vehicle registration, voter registration, and the Veterans Administration database. To be eligible 
for the MrOS study, men needed to be age 65 years and older, be able to walk without assistance 
from another person, and have had no bilateral hip replacement.  Details of the study have been 
published [21, 22].   
Between December 2009 and December 2010, recruitment   for the BMF ancillary study 
took place at the Pittsburgh clinic with a goal of 150 participants.    This sample size of 150 men 
provided sufficient power to detect a minimum correlation of 0.23 with 80 % power and  two 
sided alpha of 0.05. Men were eligible for the BMF study if they had no implants that are 
contraindicated for the magnetic resonance (MR) examination. Implants that might create a 
health risk or other problem during an MR exam include: 1) cardiac pacemaker or implantable 
defibrillator, 2) catheter that has metal components that may pose a risk of a burn injury, 3) a 
ferromagnetic metal clip placed to prevent bleeding from an intracranial aneurysm, 4) an 
implanted medication pump (such as that used to deliver insulin or a pain-relieving drug), and 5) 
a cochlear implant. At the beginning of the BMF study recruitment, the Pittsburgh MrOS clinic 
had 745 active (74%), 222 deceased (22%), and 38 withdrawn (4%) participants. Of 745 active 
participants, 53 men were not able to participate in clinic visits because they lived out–of-the-
area, agreed to post card follow-up only, or were in the care of someone else. The recruitment 
goals were reached after a total of 364 men were contacted for participation in this study. Among 
them, 130 were ineligible for MR (36%), 73 refused to participate (20%), and 159 (44%) 
completed the BMF study. We excluded two scans that were corrupted during file transfer and 
one scan with extremely low BMF likely due to treatment of the individual’s illness. Therefore, 
our analytical sample size for this study was 156.  All men had dual energy x-ray absorptiometry 
(DXA) scans for BMD, and a clinical interview/examination for anthropometric measurements, 
medical history, and lifestyle information. Fasting blood samples were collected for all 
participants. The institutional review board at the University of Pittsburgh approved the study 
protocol. All participants gave written informed consent.  
 
Proton magnetic resonance spectroscopy (1H-MRS) 
Acquiring BMF at the peripheral skeletal sites was not suitable for our study population 
due to the lack of fatty and hematopoietic marrow conversion in long bones at this age. 
Therefore, BMF content was quantified at three vertebral levels of the lumbar spine.  1H-MRS 
was performed on two Trio Siemens (3.0 Tesla) MRI scanners equipped with multi-channel 
reception capabilities. Subjects were positioned head first in the magnet bore in the supine 
position with their lumbar region over the spine matrix coil. After a triplane localizer sequence, a 
voxel measuring 15x15x20 mm was placed within the body of L1, L2 and L3. Single voxel 1H-
MRS data was then acquired using point-resolved spatially localized spectroscopy (PRESS) 
pulse sequence with the following parameters: TE 37 msec., TR 3000 msec., 16 averages, 1024 
data points and receiver bandwidth of 2000 Hz. Fitting of the spectra was done with jMRUI 
software. Water and fat peaks were identified based on published prior knowledge with water at 
~ 4.6 ppm and methylene at~ 1.3 ppm [1]. Fitting parameters included line width, amplitude and 
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shift of each peak. Fat content was defined as percent total fat over the sum of total fat and water:  
Fat content = (Ifat)/(Ifat+ Iwater) * 100% [23] . 
Fat content was measured from each vertebra from L1 to L3. As the BMF of each 
vertebra was strongly associated with each other (L1 vs L2, r=0.86, p<0.0001; L2 vs. L3, r=0.85, 
p<0.0001; L1 vs. L3, r=0.82, p<0.0001), the average fat content across all 3 levels was 
computed. When one value was missing due to vertebrae inhomogeneity or poor fitting (8 
missing for L1, 2 for L2, 3 for L3 out of the 156 subjects), the mean was computed on the other 2 
levels.   A test-retest trial was performed prior to recruitment to ensure scan quality within and 
between the two MR machines. Volunteers were scanned twice at each machine and were 
repositioned between the first and second set of scans by the same technician. The mean 
coefficient of variation (CV) for 15 pairs of vertebral BMF was 3.8% with a Pearson correlation 
coefficient of 0.98.  The intra-scanner CV (between the 2 MR machines) was 6.3% with a 
Pearson correlation of 0.99.  
 
Bone mineral density 
Areal BMD of the lumbar spine, total hip and femoral neck were measured using dual-
energy X-ray absorptiometry (DXA) (QDR 4500W, Hologic Inc., New Bedford, MA). All 
measurements of hip BMD were made on the right hip, unless the participant reported a right hip 
replacement or metal objects in the right leg, in which case the left hip was measured.  Extensive 
quality assurance protocols were used throughout the study including central training and 
certification of technicians and regular phantom scans within and across centers.  
 
Volumetric BMD  
Volumetric BMD was measured using peripheral quantitative computed tomography 
(pQCT).  A pQCT scan of the radius and tibia was performed using the Stratec XCT-2000 
(Stratec Medizintechnik, Pforzheim, Germany).   Trained technicians followed a standardized 
protocol for subject positioning and scanning. A scout view was obtained prior to the pQCT scan 
to define an anatomic reference line for the relative location of the subsequent scans at the radius 
and tibia.  Tibia length was determined from the medial malleolus to the medial condyle of the 
tibia, and forearm length was determined from the olecranon to the ulna styloid process. Scans 
were taken at four different sites: 4% and 33% of the total length of radius and tibia. The scans at 
the 4% radius and tibia sites represent predominantly trabecular bone, whereas the scans at the 
33% site represent predominantly cortical bone. A single axial slice of 2.5-mm  thickness with a 
voxel size of 0.5 mm and a speed of 20 mm/s was taken at all locations.  Image processing was 
performed by a single investigator using the Stratec software package (version 5.5E).  Daily 
phantom scans were analyzed to ensure long-term scanner stability.   
 
Laboratory assays 
Serum specimens were collected after an overnight fast and stored at –70°C until assay. 
Leptin, adiponectin, insulin and glucose were measured in the Heinz Nutrition Laboratory at the 
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Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh. 
Leptin, adiponectin and insulin were measured using RIA developed by Linco Research, Inc. (St. 
Charles, MO). For leptin, a complete set of blank, standards (0.5 ng/ml to 100 ng/ml) and quality 
controls were run with each assay, and the intrassay and interassay CV were 6.6 ± 0.8% and 5.5 
± 0.9%, respectively. The CV for adiponectin and insulin were 8.0% and 2.6%, respectively. 
Serum glucose was quantitatively determined by an enzymatic method in a procedure similar to 
that described by Bondar and Mead [24] and utilized the coupled enzyme reactions catalyzed by 
hexokinase and glucose-6-phosphate dehydrogenase. The coefficient of variation was 1.8%. 
 
Other measurements  
All participants completed a self-administered questionnaire, which included self-
reported medical history, health behaviors, and medication inventory.  Height was measured on a 
wall-mounted Harpenden stadiometer, and weight was measured on a standard balance beam 
scale using standard protocols. Body mass index (BMI) was calculated as weight in kilograms 
divided by height in meters squared (kg/m2).Waist circumference was measured at the level of 
the umbilicus. In the current study, diabetes was defined by self-reported physician’s diagnosis 
of the disease, use of diabetes medication(s) or a fasting plasma glucose level >126 mg/dl. 
 
Statistical analysis 
Characteristics of study participants by diabetic status were compared using two-sample 
t-tests for normally distributed continuous variables, Wilcoxon rank sum test for non-normally 
distributed continuous variables, and chi-squared test for categorical variables. Since we 
observed a higher level of BMF among men with diabetes than those without, analysis of 
covariance (ANCOVA) was used to examine whether the difference in BMF was independent of 
confounders. Age, race, and BMI were included in our base model. Leptin, adiponectin, or 
insulin concentrations were added to the base model individually to examine whether adjustment 
for these attenuates the difference in BMF by diabetic status. The associations of BMF with age 
and BMD were first evaluated using the Pearson correlation tests. A separate Pearson correlation 
test was done with stratification for diabetic status. We further used linear regression models to 
examine the association between BMF and BMD adjusting for age, race, BMI.  The interaction 
between BMF and diabetes was also examined.  All analyses were conducted using SAS version 
9.3 (SAS Institute, Cary, NC, USA). 
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Results 
The overall distribution of BMF is shown in Figure 1.  The mean (±SD) BMF was 55.7 ± 
11.0 (%) (range: 23.5% to 76.4%) among 156 men aged between 74 and 96 years old (mean age: 
80.5 ± 5.4 years), Table 1. There were only three men of African descent.  The prevalence of 
diabetes was 24% (n=38). Although body weight, BMI and waist circumference appeared to be 
higher for men with diabetes, there was no significant difference compared to men without 
diabetes. There was no differences in smoking, alcohol intake, total calcium intake (diet plus 
supplements), history of rheumatoid arthritis or use of osteoporosis medication or oral 
corticosteroids between diabetic and non-diabetic men.  Men with diabetes had a significantly 
higher BMF than those without (58.9% vs. 54.6%), p=0.035.  This difference was slightly 
greater than 1/3 of one standard deviation.  Compared to the non-diabetic men, diabetic men also 
had a significantly greater total hip, p=0.04 and lumbar spine BMD, p=0.007 but there were no 
differences in trabecular and cortical vBMD between diabetic and non-diabetic men.  In addition, 
levels of insulin were significantly higher among individuals with diabetes with no difference in 
leptin or adiponectin. 
To further investigate whether the difference in BMF between men with and without 
diabetes was independent of confounders, we compared the mean BMF between the two groups 
after adjusting for age, race and BMI (Table 2).  
We found that BMF remained significantly higher for men with diabetes, p=0.034. 
Additional inclusion of potential mediators like leptin, adiponectin or insulin did not change the 
observed difference. We excluded the 2 men who reported thiazolidinediones (TZD) use and the 
BMF remained higher in those with diabetes (58.54%) compared to non-diabetics (54.61%), 
although the difference was borderline significant, p=0.06. 
  
Fig 1.  Distribution of vertebral bone marrow fat. 
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Correlations of BMF with age and skeletal parameters are presented in Table 3. There were no 
significant correlations between BMF and age. The correlations between BMF and BMD were 
not significant in the total sample. When  stratified by diabetes status, BMF was inversely 
correlated with total hip BMD (r= -0.39, p=0.017) and femoral neck BMD (r= -0.30, p=0.064) 
but not spine BMD among men with diabetes but not among non-diabetics.  Results from linear 
regression (Figure 2) showed that the negative correlation between BMF and total hip BMD was 
stronger in men with diabetes than those without (test for interaction between BMF and diabetes, 
p=0.07).  There was no association between BMD and trabecular and cortical volumetric BMD 
overall or stratified by diabetes status.   
Table 1  Subject characteristics: Overall and by diabetes status. 
Characteristics Overall 
(N=156) 
Diabetes 
(N=38) 
Non-Diabetes 
(N=118) 
P-value a  
Age 80.5 ± 4.8 80.2 ± 5.4 80.6 ± 4.6 0.65 
African American (%) 3 (1.9) 1 (2.6) 2 (1.7) 0.57 
Weight (kg) 83.8 ± 12.5 86.6 ± 10.4 82.9 ± 13.0 0.11 
BMI (kg/m2) 28.1 ± 3.7 28.8 ± 3.1 27.9 ± 3.9 0.17 
Waist circumference (cm) 102.8 ± 10.4 104.5 ± 10.4 102.2 ± 10.3 0.23 
Smoking     
   Past 95 (60.9) 25 (65.8) 70 (59.3) 0.76 
   Current 4 (2.6) 1 (2.6) 3 (1.7) --- 
Alcohol (>1 drink/week) 80 (51.6) 19 (50.0) 61 (52.1) 0.82 
Total calcium intake (mg/d) 1097.9 (525.9) 1171.7 (681.1) 1073.8 (466.1) 0.41 
Rheumatoid arthritis 6 (3.9) 0 (0) 6 (5.1) 0.34 
Osteoporosis medication use 7 (4.5) 2 (5.3) 5 (4.2) 0.69 
Oral corticosteroid use 3 (1.9) 0 (0) 3 (2.5) 0.43 
Bone marrow fat (%) 55.7 ± 11.0 58.9 ± 10.8 54.6 ± 10.9 0.035 
Areal BMD (g/cm2)     
   Femoral neck  0.78 ± 0.13 0.81 ± 0.14 0.77 ± 0.12 0.08 
   Total hip  0.95 ± 0.15 1.00 ± 0.16 0.94 ± 0.14 0.04 
   Total spine  1.12 ± 0.20 1.20 ± 0.23 1.10 ± 0.18 0.007 
Volumetric BMD (mg/cm3)     
   Radius 4% trabecular 195.6 ± 43.9 200.1 ± 47.3 194.3 ± 43.0  0.50 
   Radius 33% cortical 229.0 ± 37.1 236.6 ± 39.9 226.5 ± 35.9 0.15 
   Tibia 4%  trabecular 1153.1 ± 38.3 1161.7 ± 33.7 1150.5 ± 39.3 0.14 
   Tibia 33%  cortical 1130.7 ± 33.3 1137 ± 29.1 1128.5 ± 34.4 0.16 
Leptin (ng/ml) b 10.7 (7.3 – 15.8) 11.2 (8.4 - 17.4) 10.4 (7.0 - 14.9) 0.19 
Adiponectin (ug/ml) b 10.8 (7-15.3) 10.6 (7.0 - 16.4) 10.9 (7.0 - 15.2) 0.95 
Insulin (uU/ml) b 14.0 (11.2 – 18.9) 16.4 (12.5 - 23.0) 13.3 (11.0 - 17.7) 0.014 
Diabetes medication (%)  21 (13.5) 21 (55.3) 0 (0.0) <0.0001 
      Metformin (%) --- 10 (26.3) --- --- 
      Thiazolidinedione (%) --- 2 (5.3) --- --- 
      Sulfonylureas (%) --- 9 (23.27) --- --- 
Values are unadjusted mean ± SD or frequency (%), unless indicated otherwise;  
a P-values are for comparison of characteristics between diabetic and non-diabetic groups 
b Values are median (interquartile range). 
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Table 2  Adjusted means for bone marrow fat by type 2 diabetes status. 
 
Models 
Diabetes 
(N = 38) 
Non-Diabetes 
(N = 118) 
 
P-value 
Age 58.96 ± 1.77 54.60 ± 1.01 0.034 
Age + Race 59.19 ± 3.53 54.83 ± 3.26 0.035 
Base Model: Age + Race + BMI  59.18 ± 3.54 54.80 ± 3.28 0.036 
Base Model + Leptin 57.56 ± 3.55 53.20 ± 3.30 0.034 
Base Model + Adiponectin 59.05 ± 3.56 54.72 ± 3.30 0.038 
Base Model + Insulin 59.17 ± 3.56 54.80 ± 3.30 0.042 
 
 
 
Table 3 Pearson correlations between bone marrow fat and age and bone 
mineral density in older men 
  
Models 
Overall 
(N = 156) 
Diabetes  
(N = 38) 
Non-Diabetes 
(N = 118) 
Age 0.04 0.06 0.03 
Areal BMD(g/cm2)    
   Femoral neck -0.05 -0.30a 0.003 
   Total hip -0.08 -0.39b -0.01 
   Total spine  -0.08 -0.08 -0.13 
Volumetric BMD (mg/cm3)    
   Radius 4% trabecular 0.08 0.07 0.07 
   Radius 33% cortical -0.08 008 -0.06 
   Tibia 4%  trabecular -0.07 -0.19 -0.14 
   Tibia 33%  cortical -0.09 0.07 -0.16 
a p < 0.10; b p < 0.05. 
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Discussion 
Our study examined the relationship between vertebral BMF and BMD at the lumbar spine and 
hip measured by DXA, and whether diabetes influenced these associations. We found a higher 
BMF content among men with diabetes than those without. Unlike previous studies, the overall 
correlation between BMF and BMD in our study was weak and not statistically significant. 
However, when participants were stratified by type 2 diabetes status, negative and moderate 
correlations were found with femoral neck and total hip BMD and BMF among men with 
diabetes.  
The use of the 1H-MRS technique enabled us to measure BMF content and evaluate its 
relationship with skeletal parameters. The overall BMF content in our study was similar to that 
reported in older Chinese men [25] and Icelandic men [12], but lower than that for 
postmenopausal Chinese women [25].  
Studies investigating this relationship often included postmenopausal women only or 
both genders with a wide age range that spanned several decades. Studies by Griffith and 
colleagues found a higher vertebral BMF content among osteoporotic Chinese men and women 
aged 60 and older, when compared with those with low or normal BMD [4-6]. The BMF content 
in the osteoporotic group was 8%, or approximately one SD, higher than the normal BMD group 
[4, 5].  
The majority of studies examining the BMF and BMD relationship in men were 
conducted in a Chinese population in Hong Kong, where a correlation of -0.21 (p=0.05) with 
spine BMD was found among men aged 61-90 years old [25]. Among the non-Asian population, 
Fig 2:  Scatterplot of the association between bone 
marrow fat and total hip bone mineral density 
stratified by diabetes status. 	
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this relationship was primarily found in women. One study reported a correlation of -0.39 
between vertebral BMF and trabecular BMD among premenopausal Caucasian women [26], 
while another reported a correlation of -0.45 among postmenopausal Caucasian women [27]. 
When BMF was measured using CT at the pelvis, its correlation with pelvic, whole-body and 
spine BMD was between -0.41 and -0.56 for men and women aged 40-88 years old. However, 
the correlations were attenuated (-0.35 to -0.40) after adjusting for age, weight and body fat [11]. 
Although the lack of an overall association between BMF and BMD in our study is unclear, it is 
possible that this relationship diminishes with older age and differs in men and women. Griffin 
and colleagues showed that when correlations between vertebral BMF and lumbar spine BMD 
were stratified by age in 10 year increments among Chinese men and women aged 61 to 90 years 
old, the correlations were weakened and no longer statistically significant for men age >71 years 
[25].  
We found no correlation between BMF and lumbar spine aBMD which may have 
reflected the larger proportion of trabecular bone in the spine.  However, we found no correlation 
between radial and tibial trabecular and cortical vBMD overall or stratified by diabetic status.  It 
is not clear why there was an association with hip aBMD but not vBMD.  Future studies will 
need to replicate these findings.   
Although results from our study may not support the inverse correlation between BMF 
and BMD overall as reported in previous studies, the significant and inverse correlations between 
BMF and hip BMD were only found among men with diabetes. A similar study design using the 
same MR technique reported an association between areal BMD and BMF in women but not 
men [12].  The lack of association with spine BMD may reflect the presence of artifact in lumbar 
area that elevates spine BMD in older adults such as osteoarthritis, scoliosis or aortic 
calcifications.   
To our knowledge, our study is one of a few to compare BMF and BMD correlations by 
diabetes status.  Baum and colleagues reported no significant difference in BMF between 
postmenopausal women with (n=13) and without (n=13) diabetes; however, they also found a 
stronger correlation between vertebral BMF and lumbar spine  volumetric BMD (measured by 
QCT) among diabetes than controls (-0.70 vs. -0.58) [27]. Changes in BMF after gastric bypass 
were compared in 11 morbidly obese women by diabetic status [28].  Despite large declines in 
body weight in both groups, there was little change in BMF in non-diabetic women but 
decreased by 7.5% over 6 months in diabetic women.  The authors hypothesized that the decline 
in BMF in diabetics may reflect better diabetes control due to their weight loss.  The underlying 
mechanism that drives the stronger bone-fat relationship in diabetic individuals is unclear and 
merits further investigation.  
While the positive association between type 2 diabetes and BMD has been widely 
reported [19, 20], the relationship between BMF and diabetes remains largely unexplored. The 
differentiation process of MSC into osteoblasts and adipocytes is determined by several 
transcriptional regulators including peroxisome	proliferator	activated	receptor	gamma  2 
(PPARɤ2) [29]. A class of diabetes medications, TZD, activates PPARɤ2 and has been shown to 
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increase adipocytes at the expense of osteoblasts in mouse models [30]. Two previously 
published studies reported divergent results on the association between TZDs and BMF. One 
study reported that the use of pioglitazone increased BMF after 6 months in both men and 
women [31], while another found a decrease in BMF after 14 weeks of rosiglitzone treatment 
among women [30]. In our study, men with diabetes had a higher BMF content than those 
without; however, this observation did not appear to be due to TZD use, since a sensitivity 
analysis, which removed two participants taking TZDs, yielded similar results. However, our 
lack of historical information on TZD use limits our ability to definitely exclude the possible role 
of TZDs in higher BMF among diabetics in our study.  
The activation of PPARɤ2 is also known to increase insulin sensitivity and adipokines 
[29]. We also evaluated whether adipokines related to insulin sensitivity had a role of mediating 
the association between BMF and diabetes status. Both leptin and adiponectin are secreted by 
adipocytes and have been known to affect bone metabolism. Leptin is highly correlated with 
body fat mass [32, 33], and increases bone formation through the proliferation of osteoblasts and 
inhibition of osteoclasts [34]; however, its association with BMD has not been consistently 
reported. Positive [35-38], negative [39-41] and null [42, 43]  associations have been found. 
Adiponectin is known to regulate insulin sensitivity, and low level of this adipocyte-producing 
hormone has been associated with the progression of diabetes. In addition, high adiponectin 
levels have been linked to lower BMD [38, 44, 45] and greater BMD loss [46, 47], and its role in 
stimulating the receptor activator of nuclear factor-κB ligand (RANKL) pathway and inhibiting 
the production of the decoy receptor for RANKL and osteoprotegerin may contribute greatly to 
this observation [48]. With the potential interplay of leptin, adiponectin and insulin with bone 
and type 2 diabetes, we further tested the effect of these factors on the observed difference in 
BMF content among diabetic and non-diabetic men.  Results showed that the differences in BMF 
by diabetic status were independent of leptin, adiponectin or insulin. More studies are needed to 
identify other pathways and factors that might bridge the connection between BMF and diabetes. 
Strengths of our study include a relatively large sample size of older men compared to 
previous studies and use of non-invasive techniques to measure BMF.  However, several 
limitations must be acknowledged. The inclusion of primarily Caucasian men limits the 
generalization of study results to other populations, especially among those of African ancestry 
who have a greater prevalence and risk for diabetes. Second, our study participants were over the 
age of 70. Additional studies with men of African ancestry and/or younger age should be carried 
out to confirm the association between BMF and BMD and its interaction with diabetes. We had 
no information on the duration and severity of diabetes or other risk factors for osteoporosis in 
older men including 25-hydroxyvitamin D or prevalence of hypogonadism.  Lastly, although our 
findings suggest an important role of diabetes on the relationship between BMF and BMD, the 
small number of diabetic cases limited our ability and statistical power to investigate this 
complex interplay.   
In conclusion, we found no association between BMF and aBMD overall in the cohort.  
However, we found that this relationship may differ by diabetic status. Compared to men without 
14 	
diabetes, a higher BMF and a stronger inverse correlation between BMF and BMD at the hip 
were found for men with diabetes. Our findings may suggest a novel pathway of BMF in bone 
metabolism among subjects with diabetes. Individuals with type 2 diabetes are known to be more 
susceptible to fracture despite their high BMD [19]. The link between BMF and diabetes may 
provide insight into the paradoxical relationship among BMD, fracture and diabetes. With the 
increase in life expectancy and the epidemic of diabetes, understanding the underlying 
mechanisms that links diabetes with BMF and how it may affect fracture risk is essential. Future 
studies should also seek to determine whether BMF can serve as a biomarker for fracture 
prediction. 
  
15 	
Acknowledgments 
The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health 
funding. The following institutes provide support: the National Institute on Aging (NIA), the 
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National 
Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical 
Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, 
U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 
TR000128.  Additional funding was obtained from NIAMS for Dr. Cauley's grant entitled, 
"Epidemiologic Study of Bone Marrow Fat and Osteoporosis”, RC1 AR058162. 
 
  
16 	
References 
 
[1] Machann J, Stefan N, Schick F. (1)H MR spectroscopy of skeletal muscle, liver and bone 
marrow. Eur J Radiol 2008;67(2): 275-84. 
[2] Verma S, Rajaratnam JH, Denton J, Hoyland JA, Byers RJ. Adipocytic proportion of 
bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol 2002;55(9): 
693-8. 
[3] Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, Kassem M. Adipocyte 
tissue volume in bone marrow is increased with aging and in patients with osteoporosis. 
Biogerontology 2001;2(3): 165-71. 
[4] Griffith JF, Yeung DK, Antonio GE, Lee FK, Hong AW, Wong SY, Lau EM, Leung PC. 
Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with 
osteoporosis: dynamic contrast-enhanced MR imaging and MR spectroscopy. Radiology 
2005;236(3): 945-51. 
[5] Griffith JF, Yeung DK, Antonio GE, Wong SY, Kwok TC, Woo J, Leung PC. Vertebral 
marrow fat content and diffusion and perfusion indexes in women with varying bone density: 
MR evaluation. Radiology 2006;241(3): 831-8. 
[6] Yeung DK, Griffith JF, Antonio GE, Lee FK, Woo J, Leung PC. Osteoporosis is 
associated with increased marrow fat content and decreased marrow fat unsaturation: a proton 
MR spectroscopy study. J Magn Reson Imaging 2005;22(2): 279-85. 
[7] Shih TT, Chang CJ, Hsu CY, Wei SY, Su KC, Chung HW. Correlation of bone marrow 
lipid water content with bone mineral density on the lumbar spine. Spine (Phila Pa 1976) 
2004;29(24): 2844-50. 
[8] Schellinger D, Lin CS, Lim J, Hatipoglu HG, Pezzullo JC, Singer AJ. Bone marrow fat 
and bone mineral density on proton MR spectroscopy and dual-energy X-ray absorptiometry: 
their ratio as a new indicator of bone weakening. AJR Am J Roentgenol 2004;183(6): 1761-5. 
[9] Schellinger D, Lin CS, Hatipoglu HG, Fertikh D. Potential value of vertebral proton MR 
spectroscopy in determining bone weakness. AJNR Am J Neuroradiol 2001;22(8): 1620-7. 
[10] Tang GY, Lv ZW, Tang RB, Liu Y, Peng YF, Li W, Cheng YS. Evaluation of MR 
spectroscopy and diffusion-weighted MRI in detecting bone marrow changes in postmenopausal 
women with osteoporosis. Clin Radiol 2010;65(5): 377-81. 
[11] Shen W, Scherzer R, Gantz M, Chen J, Punyanitya M, Lewis CE, Grunfeld C. 
Relationship between MRI-measured bone marrow adipose tissue and hip and spine bone 
mineral density in African-American and Caucasian participants: the CARDIA study. J Clin 
Endocrinol Metab 2012;97(4): 1337-46. 
[12] Schwartz AV, Sigurdsson S, Hue TF, Lang TF, Harris TB, Rosen CJ, Vittinghoff E, 
Siggeirsdottir K, Sigurdsson G, Oskarsdottir D, Shet K, Palermo L, Gudnason V, Li X. Vertebral 
bone marrow fat associated with lower trabecular BMD and prevalent vertebral fracture in older 
adults. J Clin Endocrinol Metab 2013;98(6): 2294-300. 
[13] Wehrli FW, Hopkins JA, Hwang SN, Song HK, Snyder PJ, Haddad JG. Cross-sectional 
study of osteopenia with quantitative MR imaging and bone densitometry. Radiology 
2000;217(2): 527-38. 
[14] Botolin S, McCabe LR. Bone loss and increased bone adiposity in spontaneous and 
pharmacologically induced diabetic mice. Endocrinology 2007;148(1): 198-205. 
17 	
[15] Krings A, Rahman S, Huang S, Lu Y, Czernik PJ, Lecka-Czernik B. Bone marrow fat has 
brown adipose tissue characteristics, which are attenuated with aging and diabetes. Bone 
2012;50(2): 546-52. 
[16] Botolin S, Faugere MC, Malluche H, Orth M, Meyer R, McCabe LR. Increased bone 
adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic 
mice. Endocrinology 2005;146(8): 3622-31. 
[17] Slade JM, Coe LM, Meyer RA, McCabe LR. Human bone marrow adiposity is linked 
with serum lipid levels not T1-diabetes. J Diabetes Complications 2012;26(1): 1-9. 
[18] Patsch JM, Li X, Baum T, Yap SP, Karampinos DC, Schwartz AV, Link TM. Bone 
marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent 
fragility fractures. J Bone Miner Res 2013;28(8): 1721-8. 
[19] Strotmeyer ES, Cauley JA. Diabetes mellitus, bone mineral density, and fracture risk. 
Curr Opin Endocrinol Diabetes Obes 2007;14(6): 429-35. 
[20] Schwartz AV, Sellmeyer DE. Diabetes, fracture, and bone fragility. Curr Osteoporos Rep 
2007;5(3): 105-11. 
[21] Blank JB, Cawthon PM, Carrion-Petersen ML, Harper L, Johnson JP, Mitson E, Delay 
RR. Overview of recruitment for the osteoporotic fractures in men study (MrOS). Contemp Clin 
Trials 2005;26(5): 557-68. 
[22] Orwoll E, Blank JB, Barrett-Connor E, Cauley J, Cummings S, Ensrud K, Lewis C, 
Cawthon PM, Marcus R, Marshall LM, McGowan J, Phipps K, Sherman S, Stefanick ML, Stone 
K. Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large 
observational study of the determinants of fracture in older men. Contemp Clin Trials 
2005;26(5): 569-85. 
[23] Kugel H, Jung C, Schulte O, Heindel W. Age- and sex-specific differences in the 1H-
spectrum of vertebral bone marrow. J Magn Reson Imaging 2001;13(2): 263-8. 
[24] Bondar RJ, Mead DC. Evaluation of glucose-6-phosphate dehydrogenase from 
Leuconostoc mesenteroides in the hexokinase method for determining glucose in serum. Clin 
Chem 1974;20(5): 586-90. 
[25] Griffith JF, Yeung DK, Ma HT, Leung JC, Kwok TC, Leung PC. Bone marrow fat 
content in the elderly: a reversal of sex difference seen in younger subjects. J Magn Reson 
Imaging 2012;36(1): 225-30. 
[26] Bredella MA, Torriani M, Ghomi RH, Thomas BJ, Brick DJ, Gerweck AV, Rosen CJ, 
Klibanski A, Miller KK. Vertebral bone marrow fat is positively associated with visceral fat and 
inversely associated with IGF-1 in obese women. Obesity (Silver Spring) 2011;19(1): 49-53. 
[27] Baum T, Yap SP, Karampinos DC, Nardo L, Kuo D, Burghardt AJ, Masharani UB, 
Schwartz AV, Li X, Link TM. Does vertebral bone marrow fat content correlate with abdominal 
adipose tissue, lumbar spine bone mineral density, and blood biomarkers in women with type 2 
diabetes mellitus? J Magn Reson Imaging 2012;35(1): 117-24. 
[28] Schafer AL, Li X, Schwartz AV, Tufts LS, Wheeler AL, Grunfeld C, Stewart L, Rogers 
SJ, Carter JT, Posselt AM, Black DM, Shoback DM. Changes in vertebral bone marrow fat and 
bone mass after gastric bypass surgery: A pilot study. Bone 2015;74(140-5. 
[29] Kawai M, Devlin MJ, Rosen CJ. Fat targets for skeletal health. Nat Rev Rheumatol 
2009;5(7): 365-72. 
[30] Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. 
Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. 
Endocrinology 2007;148(6): 2669-80. 
18 	
[31] Grey A, Beckley V, Doyle A, Fenwick S, Horne A, Gamble G, Bolland M. Pioglitazone 
increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial. Eur J 
Endocrinol 2012;166(6): 1087-91. 
[32] Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 
2001;104(4): 531-43. 
[33] Flier JS. Clinical review 94: What's in a name? In search of leptin's physiologic role. J 
Clin Endocrinol Metab 1998;83(5): 1407-13. 
[34] Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human 
marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to 
adipocytes. Endocrinology 1999;140(4): 1630-8. 
[35] Weiss LA, Barrett-Connor E, von Muhlen D, Clark P. Leptin predicts BMD and bone 
resorption in older women but not older men: the Rancho Bernardo study. J Bone Miner Res 
2006;21(5): 758-64. 
[36] Pasco JA, Henry MJ, Kotowicz MA, Collier GR, Ball MJ, Ugoni AM, Nicholson GC. 
Serum leptin levels are associated with bone mass in nonobese women. J Clin Endocrinol Metab 
2001;86(5): 1884-7. 
[37] Thomas T, Burguera B, Melton LJ, 3rd, Atkinson EJ, O'Fallon WM, Riggs BL, Khosla S. 
Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship 
between fat mass and bone mineral density in men versus women. Bone 2001;29(2): 114-20. 
[38] Barbour KE, Zmuda JM, Boudreau R, Strotmeyer ES, Horwitz MJ, Evans RW, Kanaya 
AM, Harris TB, Cauley JA, Health ABCS. The effects of adiponectin and leptin on changes in 
bone mineral density. Osteoporos Int 2012;23(6): 1699-710. 
[39] Jurimae J, Jurimae T, Leppik A, Kums T. The influence of ghrelin, adiponectin, and 
leptin on bone mineral density in healthy postmenopausal women. J Bone Miner Metab 
2008;26(6): 618-23. 
[40] Lorentzon M, Landin K, Mellstrom D, Ohlsson C. Leptin is a negative independent 
predictor of areal BMD and cortical bone size in young adult Swedish men. J Bone Miner Res 
2006;21(12): 1871-8. 
[41] Ruhl CE, Everhart JE. Relationship of serum leptin concentration with bone mineral 
density in the United States population. J Bone Miner Res 2002;17(10): 1896-903. 
[42] Morberg CM, Tetens I, Black E, Toubro S, Soerensen TI, Pedersen O, Astrup A. Leptin 
and bone mineral density: a cross-sectional study in obese and nonobese men. J Clin Endocrinol 
Metab 2003;88(12): 5795-800. 
[43] Martini G, Valenti R, Giovani S, Franci B, Campagna S, Nuti R. Influence of insulin-like 
growth factor-1 and leptin on bone mass in healthy postmenopausal women. Bone 2001;28(1): 
113-7. 
[44] Basurto L, Galvan R, Cordova N, Saucedo R, Vargas C, Campos S, Halley E, Avelar F, 
Zarate A. Adiponectin is associated with low bone mineral density in elderly men. Eur J 
Endocrinol 2009;160(2): 289-93. 
[45] Jurimae J, Jurimae T. Adiponectin is a predictor of bone mineral density in middle-aged 
premenopausal women. Osteoporos Int 2007;18(9): 1253-9. 
[46] Jurimae J, Kums T, Jurimae T. Adipocytokine and ghrelin levels in relation to bone 
mineral density in physically active older women: longitudinal associations. Eur J Endocrinol 
2009;160(3): 381-5. 
19 	
[47] Araneta MR, von Muhlen D, Barrett-Connor E. Sex differences in the association 
between adiponectin and BMD, bone loss, and fractures: the Rancho Bernardo study. J Bone 
Miner Res 2009;24(12): 2016-22. 
[48] Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, Liao EY. Adiponectin stimulates 
RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling 
pathway. J Bone Miner Res 2006;21(10): 1648-56. 
 
 
